NextCure, Inc. (NXTC): Nasdaq/NYSE listing notice — NextCure receives Nasdaq bid price deficiency notice; has until July 30, 2025 to regain compliance

NextCure, Inc.

Nasdaq notified NextCure that its closing bid price was below $1.00 for 30 consecutive business days.
Company has 180-day grace period ending July 30, 2025 to meet the $1.00 minimum bid for 10 consecutive days.
If not compliant, NextCure may seek an additional 180-day extension if it meets other listing standards.
The company is evaluating options including a reverse stock split; delisting risk remains.
No immediate effect on trading; stock continues trading on Nasdaq Global Select Market.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

NextCure, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

January 31, 2025, NextCure, Inc. (the “Company”, “we”, “us”, or “our”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying us that the closing price of our common stock over the prior 30 consecutive business days had fallen below $1.00 per share, which is the minimum average closing price required to maintain listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have 180 calendar days, or until J

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

NextCure, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

January 31, 2025, NextCure, Inc. (the “Company”, “we”, “us”, or “our”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying us that the cl

View on SEC.gov

Browse all listing & compliance notices →

NextCure, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-25-000603

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.